Viral resistance and CMV retinitis: design and methods of a prospective study

References

• Holland G N, Pepose J S, Pettit T H, Gottlieb M S, Yee R D, Foos R Y. Acquired immune deficiency syndrome: Ocular manifestations. Ophthalmology 1983; 90: 859–73
   PubMed Web of Science ®Google Scholar
• Palestine A G, Rodrigues M M, Macher A M, Chan C C, Lane C H, Fauci A S, Masur H, Longo D, Reichert C M, Steis R, Rook A H, Nussenblatt R B. Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology 1984; 91: 1092–9
   PubMed Web of Science ®Google Scholar
• Freeman W R, Lerner C W, Mines J A, Lash R S, Nadel A J., Starr M B, Tapper M L. A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome. Am J Ophthalmol 1984; 97: 133–42
   PubMed Web of Science ®Google Scholar
• Pepose J S, Holland G N, Nestor M S, Cochran A J, Foos R Y. Acquired immune deficiency syndrome: Pathogenic mechanisms of ocular disease. Ophthalmology 1985; 92: 472–84
   PubMed Web of Science ®Google Scholar
• Jacobson M A, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988; 108: 585–94
   PubMed Web of Science ®Google Scholar
• Jabs D A, Enger C, Bartlett J G. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989; 107: 75–80
   PubMed Web of Science ®Google Scholar
• Hoover D R, Saah A J, Bacellar H, Phair J, Detels R, Anderson R, Kaslow R A. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993; 329: 1922–6
   PubMed Web of Science ®Google Scholar
• Studies of Ocular Complications of AIDS (SOCA) Research Group, in collaboration with the AIDS Clinical Trials Group (ACTG). Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326: 213–20
   Google Scholar
• Pertel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J AIDS 1992; 5: 1069–74
   PubMed Web of Science ®Google Scholar
• Gallant J E, Moore R D, Richman D D, Keruly J, Chaisson R E, Zidovudine Epidemiology Study Group. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992; 166: 1223–7
   PubMed Web of Science ®Google Scholar
• Kuppermann B D, Petty J G, Richman D D, Mathews C W, Fullerton S C, Rickman L S, Freeman W R. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1993; 115: 575–82
   PubMed Web of Science ®Google Scholar
• Jacobson M A, O'Donnell J J, Porteous D, Brodie H R, Feigal D, Mills J. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: Prevalence, natural history, and response to ganciclovir therapy. Quart J Med 1988; 67: 473–86
   PubMedGoogle Scholar
• Lehoang P, Girard B, Robinet M, Marcel P, Zazoun L, Matheron S, Rozenbaum W, Katlama C, Morer I, Lernestedt J O, Saraux H, Pouliquen Y, Gentilini M, Rousselie F. Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1989; 96: 865–74
   PubMed Web of Science ®Google Scholar
• Palestine A G, Polis M A, De Smet M D, Baird B F, Falloon J, Kovacs J S, Davey R T, Zurlo J J, Zunich K M, Davis M, Hubbard L, Brothers R, Ferris F, Chew L. E, Davis J L, Rubin B I, Mellow S D, Metcalf J A, Manischewitz J, Minor J R, Nussenblatt R B, Masur H, Lane H C. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991; 115: 665–73
   PubMed Web of Science ®Google Scholar
• Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(1,3-dihy-droxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 1986; 314: 801–5
   PubMed Web of Science ®Google Scholar
• Holland G N, Sidikaro Y, Kreiger A E, Hardy D, Sakamoto M J, Frenkel L M, Winston D J, Gottlieb M S, Bryson Y J, Champlin R E, Ho W G, Winters R E, Wolfe P R, Cherry J D. Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology 1987; 94: 815–23
   PubMed Web of Science ®Google Scholar
• Laskin O L, Cederberg D M, Mills J, Eron L J, Mildvan D, Spector S A. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med 1987; 83: 201–7
   PubMed Web of Science ®Google Scholar
• Jabs D A, Newman C, de Bustros S, Polk B F. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 1987; 94: 824–30
   PubMed Web of Science ®Google Scholar
• Henderly D E, Freeman W R, Causey D M, Rao N A. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 1987; 94: 425–34
   PubMed Web of Science ®Google Scholar
• Orellana J, Teich S A, Friedman A H, Lerebours F, Winterkorn J, Mildvan D. Combined short- and long-term therapy for the treatment of cytomegalovirus retinitis using ganciclovir (BW B759U). Ophthalmology 1987; 94: 831–8
   PubMed Web of Science ®Google Scholar
• Gross J G, Bozzette S A, Mathews W C, Spector S A, Abramson I S, McCutchan A, Mendez T, Munguia D, Freeman W R. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1990; 97: 681–6
   PubMed Web of Science ®Google Scholar
• Holland G N, Shuler J D. Progression rates of cytomegalovirus retinopathy in ganciclovir-treated and untreated patients. Arch Ophthalmol 1992; 110: 1435–42
   PubMedGoogle Scholar
• Studies of Ocular Complications of AIDS (SOCA) Research Group, in collaboration with the AIDS Clinical Trials Group (ACTG). Foscarnet-ganciclovir cytomegalovirus retinitis trial: 4. Visual outcomes. Ophthalmology 1994; 101: 1250–61
   Google Scholar
• Flores-Aguilar M, Kuppermann B D, Quiceno J I, Dankner W M., Wolf D G, Capparelli E V, Connor J D, Sherwood C H, Fullerton S, Gambertoglio J G, Spector S A, Freeman W R. Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis. Ophthalmology 1993; 100: 1022–31
   PubMed Web of Science ®Google Scholar
• Drew W L, Miner R C, Busch D F, Follansbee S E, Gullett J, Mehalko S G, Gordon S M, Owen W F, Matthews T R, Buhles W C, DeArmond B. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991; 163: 716–9
   PubMed Web of Science ®Google Scholar
• Dunn J P, MacCumber M W, Forman M S, Charache P, Apuzzo L, Jabs D A. Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. Am J Ophthalmol 1995; 119: 587–96
   PubMed Web of Science ®Google Scholar
• Studies of Ocular Complications of AIDS(SOCA) Research Group, in collaboration with the AIDS Clinical Trials Group (ACTG). Foscarnet-ganciclovir cytomegalovirus retinitis trial: 1. Rationale, design, and methods. Controlled ClinTrials 1992; 13: 22–39
   Google Scholar
• Holland G N, Buhles W, Mastre C. B, Kaplan H J, the UCLA CMV Retinopathy Study Group. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy: Use of a standardized system for the assessment of disease outcome. Arch Ophthalmol 1989; 107: 1759–66
   PubMed Web of Science ®Google Scholar
• Ferris F L, Kassoi T A, Bresnick G H., Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982; 94: 91–6
   PubMed Web of Science ®Google Scholar
• Azen S P, Irvine A R, Davis M D, Stern W, Lonn L, Hilton G, Schwartz A, Boone D, Quillen-Thomas B, Lyons M, Lean J S, The Silicone Study Group. The validity and reliability of photographic documentation of proliferative vitreo-retinopathy. Ophthalmology 1989; 96: 352–7
   PubMed Web of Science ®Google Scholar
• Hoffman R A, Kung P C, Hansen W P, Goldstein G. Simple and rapid measurement of human T lymphocytes and their subclasses in peripheral blood. Proc Natl Acad Sci USA 1980; 77: 4914–7
   PubMed Web of Science ®Google Scholar
• Giorgi J V, Cheng H L, Margolick J B, Bauer K D, Ferbas J, Waxdal M, Schmid I, Hultin L E, Jackson A L, Park L, Taylor J MG, the Multicenter AIDS Cohort Study Group. Quality control in the flow cytometric measurement of T-lymphocyte subsets: The multicenter AIDS cohort study experience. Clin Immunol Immunopathol 1990; 55: 173–86
   PubMedGoogle Scholar
• Schenker E L, Hultin L E, Bauer K D, Ferbas J, Margolick J B, Giorgi J V. Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. Cytometry 1993; 14: 307–17
   Google Scholar
• Danker W M, Scholl D, Stanat S C, Martin M, Sonke R L, Spector S A. Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus. J Virol Methods 1990; 28: 293–8
   Google Scholar
• Drew W L, Miner R C, Saleh E. Antiviral susceptibility of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagn Virol 1993; 1: 179–85
   Google Scholar
• Margolick J B, Scott E R, Chadwick K R, Shapiro H M, Hetzel A D, Smith S J, Vogt R F. Comparison of lymphocyte immunophenotypes obtained simultaneously from two different data acquisition and analysis systems on the same flow cytometer. Cytometry 1992; 13: 198–203
   Google Scholar
• Biron E., Swierkosz K. Antiviral susceptibility testing. Clinical Microbiology Procedure Handbook Supplement II, H D Isenberg. American Society for Microbiology, Washington, DC 1994; 8.26.1–8.26.21
   Google Scholar
• Lachin J M. Introduction to sample size determination and power analysis for clinical trials. Controlled Clin Trials 1981; 2: 93–113
   PubMedGoogle Scholar
• Erice A, Chou S, Biron K K, Stanat S C, Balfour H H., Jr, Jordan M C. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989; 320: 289–93
   PubMed Web of Science ®Google Scholar
• Stanat S C, Reardon J E, Erice A, Jordan M C, Drew W L., Biron K K. Ganciclovir-resistant cytomegalovirus clinical isolates: Mode of resistance to ganciclovir. Antimicrob Agents Chemother 1991; 35: 2191–7
   PubMed Web of Science ®Google Scholar
• Knox K K, Drobyski W R, Carrigan D R. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient [letter]. Lancet 1991; 337: 1292–3
   PubMed Web of Science ®Google Scholar
• Sullivan V, Coen D M. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. J Infect Dis 1991; 164: 781–4
   PubMed Web of Science ®Google Scholar
• Jabs D A. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc 1995; 93: 623–83
   PubMedGoogle Scholar
• Drew W L, Sweet E S, Miner R C, Mocarski E S. Multiple infections by cytomegalovirus in patients with acquired immunodeficiency syndrome: Documentation by Southern blot hybridization. J Infect Dis 1984; 150: 952–3
   Google Scholar
• Spector S A, Hirata K K, Neuman T R. Identification of multiple cytomegalovirus strains in homosexual men with acquired immunodeficiency syndrome. J Infect Dis 1984; 150: 953–6
   PubMed Web of Science ®Google Scholar